Cargando…
Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel
BACKGROUND: The clinical role of perfusion-weighted MRI (PWI) in head and neck squamous cell carcinoma (HNSCC) remains to be defined. The aim of this study was to provide evidence-based recommendations for the use of PWI sequence in HNSCC with regard to clinical indications and acquisition parameter...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759606/ https://www.ncbi.nlm.nih.gov/pubmed/36528678 http://dx.doi.org/10.1186/s13244-022-01317-1 |
_version_ | 1784852270168408064 |
---|---|
author | Romeo, Valeria Stanzione, Arnaldo Ugga, Lorenzo Cuocolo, Renato Cocozza, Sirio Quarantelli, Mario Chawla, Sanjeev Farina, Davide Golay, Xavier Parker, Geoff Shukla-Dave, Amita Thoeny, Harriet Vidiri, Antonello Brunetti, Arturo Surlan-Popovic, Katarina Bisdas, Sotirios |
author_facet | Romeo, Valeria Stanzione, Arnaldo Ugga, Lorenzo Cuocolo, Renato Cocozza, Sirio Quarantelli, Mario Chawla, Sanjeev Farina, Davide Golay, Xavier Parker, Geoff Shukla-Dave, Amita Thoeny, Harriet Vidiri, Antonello Brunetti, Arturo Surlan-Popovic, Katarina Bisdas, Sotirios |
author_sort | Romeo, Valeria |
collection | PubMed |
description | BACKGROUND: The clinical role of perfusion-weighted MRI (PWI) in head and neck squamous cell carcinoma (HNSCC) remains to be defined. The aim of this study was to provide evidence-based recommendations for the use of PWI sequence in HNSCC with regard to clinical indications and acquisition parameters. METHODS: Public databases were searched, and selected papers evaluated applying the Oxford criteria 2011. A questionnaire was prepared including statements on clinical indications of PWI as well as its acquisition technique and submitted to selected panelists who worked in anonymity using a modified Delphi approach. Each panelist was asked to rate each statement using a 7-point Likert scale (1 = strongly disagree, 7 = strongly agree). Statements with scores equal or inferior to 5 assigned by at least two panelists were revised and re-submitted for the subsequent Delphi round to reach a final consensus. RESULTS: Two Delphi rounds were conducted. The final questionnaire consisted of 6 statements on clinical indications of PWI and 9 statements on the acquisition technique of PWI. Four of 19 (21%) statements obtained scores equal or inferior to 5 by two panelists, all dealing with clinical indications. The Delphi process was considered concluded as reasons entered by panelists for lower scores were mainly related to the lack of robust evidence, so that no further modifications were suggested. CONCLUSIONS: Evidence-based recommendations on the use of PWI have been provided by an independent panel of experts worldwide, encouraging a standardized use of PWI across university and research centers to produce more robust evidence. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13244-022-01317-1. |
format | Online Article Text |
id | pubmed-9759606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-97596062022-12-19 Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel Romeo, Valeria Stanzione, Arnaldo Ugga, Lorenzo Cuocolo, Renato Cocozza, Sirio Quarantelli, Mario Chawla, Sanjeev Farina, Davide Golay, Xavier Parker, Geoff Shukla-Dave, Amita Thoeny, Harriet Vidiri, Antonello Brunetti, Arturo Surlan-Popovic, Katarina Bisdas, Sotirios Insights Imaging Guideline BACKGROUND: The clinical role of perfusion-weighted MRI (PWI) in head and neck squamous cell carcinoma (HNSCC) remains to be defined. The aim of this study was to provide evidence-based recommendations for the use of PWI sequence in HNSCC with regard to clinical indications and acquisition parameters. METHODS: Public databases were searched, and selected papers evaluated applying the Oxford criteria 2011. A questionnaire was prepared including statements on clinical indications of PWI as well as its acquisition technique and submitted to selected panelists who worked in anonymity using a modified Delphi approach. Each panelist was asked to rate each statement using a 7-point Likert scale (1 = strongly disagree, 7 = strongly agree). Statements with scores equal or inferior to 5 assigned by at least two panelists were revised and re-submitted for the subsequent Delphi round to reach a final consensus. RESULTS: Two Delphi rounds were conducted. The final questionnaire consisted of 6 statements on clinical indications of PWI and 9 statements on the acquisition technique of PWI. Four of 19 (21%) statements obtained scores equal or inferior to 5 by two panelists, all dealing with clinical indications. The Delphi process was considered concluded as reasons entered by panelists for lower scores were mainly related to the lack of robust evidence, so that no further modifications were suggested. CONCLUSIONS: Evidence-based recommendations on the use of PWI have been provided by an independent panel of experts worldwide, encouraging a standardized use of PWI across university and research centers to produce more robust evidence. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13244-022-01317-1. Springer Vienna 2022-12-17 /pmc/articles/PMC9759606/ /pubmed/36528678 http://dx.doi.org/10.1186/s13244-022-01317-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Guideline Romeo, Valeria Stanzione, Arnaldo Ugga, Lorenzo Cuocolo, Renato Cocozza, Sirio Quarantelli, Mario Chawla, Sanjeev Farina, Davide Golay, Xavier Parker, Geoff Shukla-Dave, Amita Thoeny, Harriet Vidiri, Antonello Brunetti, Arturo Surlan-Popovic, Katarina Bisdas, Sotirios Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel |
title | Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel |
title_full | Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel |
title_fullStr | Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel |
title_full_unstemmed | Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel |
title_short | Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel |
title_sort | clinical indications and acquisition protocol for the use of dynamic contrast-enhanced mri in head and neck cancer squamous cell carcinoma: recommendations from an expert panel |
topic | Guideline |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759606/ https://www.ncbi.nlm.nih.gov/pubmed/36528678 http://dx.doi.org/10.1186/s13244-022-01317-1 |
work_keys_str_mv | AT romeovaleria clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT stanzionearnaldo clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT uggalorenzo clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT cuocolorenato clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT cocozzasirio clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT quarantellimario clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT chawlasanjeev clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT farinadavide clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT golayxavier clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT parkergeoff clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT shukladaveamita clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT thoenyharriet clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT vidiriantonello clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT brunettiarturo clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT surlanpopovickatarina clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel AT bisdassotirios clinicalindicationsandacquisitionprotocolfortheuseofdynamiccontrastenhancedmriinheadandneckcancersquamouscellcarcinomarecommendationsfromanexpertpanel |